Lyta 28 0.03 mg+0.15 mg+75 mg (Tablet)

Indications

• Inhibits ovulation
• Inhibits sperm from entering the uterus
• Inhibits fertilized egg from accepting by uterus
• Reduces movement of sperm by minimizing fallopian tube movement
• Suitable for women aged 15-69 years
• Effective temporary contraceptive method
• Anemia treatment due to excessive blood loss during menstruation
• Irregular menstruation cycle treatment
• Safe for breastfeeding mothers with children over 6 months old

Composition

• Each white (hormone) tablet contains Ethinylestradiol USP 0.03 mg & Levonorgestrel USP 0.15 mg
• Each brown color (iron) tablet contains Ferrous Fumarate BP 75 mg

Pharmacology

• Effective, temporary, and short-term birth control management for women
• Combines Levonorgestrel and Ethinyl Estradiol hormones
• Contains 21 hormone tablets and 7 iron tablets per strip
• Suppresses ovulation to lower the risk of pregnancy
• Possible mechanisms include cervical mucus changes and endometrial changes

Dosage & Administration

• Start taking from the first day of menstruation
• Take one tablet daily with food, preferably after dinner or before sleeping
• Start with one white tablet daily for 3 weeks, then one brown tablet daily for 7 days
• Continue medication even if menstruation starts during brown tablet phase
• Use condom during sexual intercourse for 7 days if starting dose after menstruation

Interaction

• Enzyme inducers may decrease effectiveness
• Counsel patients to use a backup contraception when using enzyme inducers
• Avoid caffeine, dairy foods, and phytic acid containing food while taking the drug

Contraindications

• Known hypersensitivity to any components of the product

Side Effects

• Common: headache, nausea, mood changes, vaginal infections, irregular vaginal bleeding, pain
• Rare: liver tumors, jaundice, high blood pressure, gallbladder problems

Pregnancy & Lactation

• Contraindicated in pregnancy
• Discontinue if pregnancy occurs
• Can reduce milk production in breastfeeding females

Precautions & Warnings

• Stop medication if a thrombotic disorder occurs
• Discontinue in case of jaundice
• Monitor blood pressure in women with well-controlled hypertension
• Monitor prediabetic and diabetic women
• Evaluate significant change in headaches

Use in Special Populations

• Safety and efficacy established in women of reproductive age
• Expected efficacy in post-pubertal adolescents under 18 years
• Not indicated for use before menarche

Overdose Effects

• No reports of serious illness effects from overdose
• May cause withdrawal bleeding and nausea

Therapeutic Class

• Oral Contraceptive preparations

Storage Conditions

• Store below 30°C, protected from light and moisture
• Keep all medicines out of reach of children

Related Brands